Cytokinetics abandons ALS drug after failed trial, shares tank

(Reuters) – Cytokinetics Inc will stop developing one of its treatments for ALS, which afflicts Stephen Hawking, after the drug failed in a late-stage trial, the company said on Tuesday, sending its shares tumbling about 35 percent.


Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *